Lymphatic invasion as a prognostic factor for non-small-cell lung cancer
The standard treatment for resectable stage I–IIIA non-small-cell lung cancer (NSCLC) is surgical resection. However, even with stage I NSCLC, patients sometimes develop a recurrence, with reported 5-year survival rates of 86.8% with stage IA and 73.9% with stage IB . Although TNM classifications can stratify patients well into different prognosis groups, stage I NSCLC is still considered as a heterogeneous group. Therefore, additional useful indicators are needed to predict survival when deciding upon treatment strategies.